Table 1 Patient demographics. For binary data, the number (n) and proportion (%) of patients are listed with the odds ratio and 95% confidence interval (CI). p-values were calculated using Chi-square or Fischer’s exact tests, as appropriate. Numerical data are listed as median and interquartile range (IQR), and p-values were calculated using non-parametric two-sided Mann-Whitney U tests. For BMI, data represent mean ± standard deviation (SD) and the p-value was calculated using a parametric two-sided student’s t-test. Pathological T- and N-stage (pT and pN) as described in the cystectomy specimen. BMI: body mass index, ASA: American society of anesthesiologists, CCI: Charlson comorbidity score, DM2: diabetes mellitus type 2, CKD: chronic kidney disease, G: grade
Total | Sutured | Stapled | Odds ratio (95% CI) | p | |
|---|---|---|---|---|---|
Preoperative characteristics | |||||
Patients, n (%) | 92 (100.00) | 59 (64.13) | 33 (35.87) | ||
Age, median (IQR) | 71 (65.25-77) | 71 (65–76) | 70 (65–77) | — | 0.813 |
Sex, n males (%) | 74 (80.43) | 48 (81.36) | 26 (78.79) | 1.18 (0.44–3.17) | 0.766 |
BMI, mean (± SD) | 26.73 (± 4.49) | 25.97 (± 4.20) | 28.09 (± 4.73) | — | 0.029 |
ASA, median (IQR) | 3 (2–3) | 3 (2–3) | 2 (2–3) | — | 0.030 |
Pack years, median (IQR) | 15 (0–40) | 15 (0–35) | 11 (0–54) | — | 0.697 |
CCI (IQR) | 5 (4–7) | 5 (4–7) | 5 (4-7.5) | — | 0.898 |
DM2, n (%) | 18 (19.57) | 10 (16.95) | 8 (24.24) | 0.64 (0.23–1.92) | 0.398 |
Vascular disease, n (%) | 27 (29.35) | 20 (33.90) | 7 (21.21) | 1.91 (0.75–4.82) | 0.200 |
CKD stage (GFR), n (%) | 0.501 | ||||
Stage G1-G2 | 69 (75.00) | 43 (72.88) | 26 (78.79) | 0.71 (0.28–1.90) | |
Stage G3-G5 | 23 (25.00) | 16 (27.12) | 7 (21.21) | ||
Previous abdominal surgery, n (%) | 48 (52.17) | 30 (50.85) | 18 (54.55) | 0.86 (0.36–2.02) | 0.733 |
Neo-adjuvant chemotherapy, n (%) | 31 (33.70) | 19 (32.20) | 12 (36.36) | 0.83 (0.33–1.99) | 0.686 |
Indication for cystectomy | |||||
Bladder cancer, n (%) | 85 (92.39) | 56 (94.92) | 29 (87.88) | 2.58 (0.65–10.64) | 0.245 |
Invasive prostate cancer, n(%) | 4 (4.35) | 3 (5.08) | 1 (3.03) | 1.71 (0.25–22.89) | > 0.999 |
Functional, n (%) | 16 (17.39) | 8 (13.56) | 8 (24.24) | 0.49 (0.17–1.57) | 0.195 |
Pathological stage | |||||
pT, n (%) | 0.717 | ||||
Benign | 6 (6.52) | 3 (5.08) | 3 (9.09) | 0.54 (0.12–2.42) | |
pT0 | 26 (28.26) | 17 (28.81) | 9 (27.27) | 1.08 (0.44–2.66) | |
pTa | 3 (3.26) | 2 (2.29) | 1 (3.03) | 1.12 (0.13–16.73) | |
pT1 | 3 (3.26) | 1 (1.69) | 2 (6.06) | 0.27 (0.02–2.40) | |
pTis | 20 (21.74) | 15 (25.42) | 5 (15.15) | 1.90 (0.62–5.17) | |
pT2 | 13 (14.13) | 9 (15.25) | 4 (12.12) | 1.31 (0.38–4.10) | |
pT3 | 16 (17.39) | 10 (16.95) | 6 (18.18) | 0.92 (0.31–2.93) | |
pT4 | 5 (5.43) | 2 (3.39) | 3 (9.09) | 0.35 (0.06–1.82) | |
pN, n (%) | 0.185 | ||||
pN0 | 72 (87.80) | 51 (91.07) | 21 (80.77) | 2.43 (0.68–8.61) | |
pN1 | 3 (3.66) | 1 (1.79) | 2 (7.69) | 0.22 (0.01–1.99) | |
pN2 | 5 (6.10) | 3 (5.36) | 2 (7.69) | 0.68 (0.13–4.04) | |
pN3 | 2 (2.44) | 1 (1.79) | 1 (3.85) | 0.45 (0.02–8.96) | |